Dilapan-S与标准方法用于足月妊娠宫颈成熟的个体患者数据Meta分析
本研究为个体患者数据系统综述与Meta分析,纳入4项随机对照试验共1731名足月单胎引产孕妇,比较Dilapan-S与其他宫颈成熟方法的剖宫产率。结果显示两组调整后剖宫产率无差异(OR 1.03,95%CI 0.8-1.3),贝叶斯推断非劣效概率95%;经产妇用Dilapan-S剖宫产率可能降低(RR 0.61,95%CrI 0.4-0.9),初产妇未见获益(RR 1.13,95%CrI 0.97-1.33)。
要点
- Dilapan-S组剖宫产率28%,其他方法组30%,调整后无显著差异(OR 1.03,95%CI 0.8-1.3)。
- 经产妇用Dilapan-S剖宫产率可能降低(RR 0.61,95%CrI 0.4-0.9),初产妇无显著获益。
- Dilapan-S组疼痛评分≥4分比例更低(46% vs 62%;OR 0.5,95%CI 0.40-0.64),满意度更高。
核心结论
- Dilapan-S在降低剖宫产率方面至少不劣于其他引产前宫颈成熟剂,且可能略有优势。
- 产次影响疗效,经产妇获益最大。
研究设计与样本
- 系统综述与个体患者数据Meta分析,检索1994年1月至2023年4月Ovid MEDLINE、Embase、Ovid Emcare、CINAHL Plus、ClinicalTrials.gov、euclinicaltrialsregister.eu和Scopus数据库。
- 纳入4项随机对照试验,共1731名足月单胎引产孕妇,其中1036名分配至Dilapan-S组,695名分配至其他宫颈成熟方法组。
- 主要结局为剖宫产率,采用频率学派和贝叶斯方法计算调整母亲年龄和产次的合并OR及95%CI。
主要发现
- Dilapan-S组剖宫产率28%,其他方法组30%,调整后无差异(OR 1.03,95%CI 0.8-1.3)。
- 贝叶斯推断显示Dilapan-S非劣效(5%界值)概率95%,劣于其他方法的概率4.5%。
- 亚组分析显示与产次存在显著交互作用:经产妇用Dilapan-S降低剖宫产率的概率99%(RR 0.61,95%CrI 0.4-0.9),初产妇获益概率6%(RR 1.13,95%CrI 0.97-1.33)。
- Dilapan-S组疼痛评分≥4分比例显著更低(46% vs 62%;OR 0.5,95%CI 0.40-0.64)。
- 宫颈成熟期间并发症(子宫高张力、子宫过速收缩、胎心监护异常等)Dilapan-S组更低(19% vs 47%;OR 0.28,95%CI 0.28-0.37),患者满意度更高。
关键数值与推荐
- 纳入标准:随机对照试验,受试者为妊娠晚期单胎引产,至少一组使用Dilapan-S进行宫颈成熟。
- 排除标准:妊娠37周前引产或认为无需宫颈成熟者。
- 预设亚组分析包括产次、体重指数、Bishop评分和孕龄。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Dilapan-S is a cervical ripening agent approved by the FDA that has been found to be just as effective as other agents and can be utilized for outpatient ripening. No large-scale studies have been conducted to compare cesarean delivery rates between Dilapan-S and other ripening methods. Our objective was to combine these trials to compare cesarean delivery rates for Dilapan-S with other cervical ripening methods, overall and in sub-groups. DATA SOURCES: The time period for this study was from January 1994 to April 2023. Ovid MEDLINE, Embase via Ovid, Ovid Emcare, CINAHL Plus, ClinicalTrials.gov, euclinicaltrialsregister.eu, and Scopus were searched. The study was conducted according to the Preferred Reporting Item for Systematic Reviews guidelines and was registered with PROSPERO (CRD42023423573). STUDY ELIGIBILITY CRITERIA: This was a systematic review and meta-analysis of individual patient data from randomized controlled trials comparing Dilapan-S to other mechanical or pharmacologic cervical ripening methods for labor induction in singleton gestations. The main outcome measure assessed was the cesarean delivery (CD) rate in comparing Dilapan-S to alternative methods. Secondary maternal outcomes included changes in Bishop score postintervention, vaginal delivery without complications, postpartum hemorrhage, cervical ripening issues, uterine infection, and patient satisfaction. Secondary neonatal outcomes were Apgar score <7 at 5 minutes, arterial cord pH <7.1, meconium presence, NICU admission and length of stay, hypoxic-ischemic encephalopathy, intraventricular hemorrhage, infant infection, and infant death. This study exclusively included randomized controlled trials (RCTs) involving participants who underwent labor induction during the third trimester of a singleton pregnancy. At least one group within these trials received Dilapan-S for the purpose of cervical ripening. Trials were excluded if induction occurred prior to 37 weeks of gestation or if cervical ripening was deemed unnecessary. STUDY APPRAISAL AND SYNTHESIS: Two reviewers independently selected studies, assessed the risk of bias using the Cochrane Risk of Bias Tool for RCTs, and extracted the data. Prespecified subgroup analysis was performed for parity, body mass index, Bishop score, and gestational age. Pooled odds ratios (ORs) adjusted for maternal age and parity with 95% confidence intervals (CI) were calculated using frequentist and Bayesian approaches. RESULTS: Four RCTs were identified, with 1731 women included (1036 allocated to Dilapan-S; 695 to alternative cervical ripening methods). CD rates were 28% and 30% with Dilapan-S and other methods, respectively. There was no difference in maternal age and parity-adjusted CD rates between Dilapan-S and other methods (OR 1.03, 95% CI 0.8-1.3). Bayesian inference indicated a 95% probability of being noninferior (5% margin) and a 4.5% probability of being inferior to other methods. Subgroup analysis demonstrated significant interaction with parity with a 99% probability of lowering cesarean rates among multiparous women treated with Dilapan-S (RR 0.61, 95% CrI 0.4-0.9) compared to a 6% probability of benefit among nulliparous women (RR 1.13, 95% CrI 0.97-1.33). Pain levels ≥4 were significantly lower in the Dilapan-S group (46% vs 62%; OR 0.5, 95% CI 0.40-0.64). Complication rates during cervical ripening (uterine hypertonus, uterine tachysystole, nonreassuring fetal heart tracing, and others) were also lower in the Dilapan-S group (19% vs 47%; OR 0.28, 95% CI 0.28-0.37). Higher patient satisfaction was reported with Dilapan-S. CONCLUSION: Dilapan-S was at least noninferior and marginally superior in lowering cesarean rates compared to other preinduction cervical ripening agents. Parity impacted efficacy, with multiparous women benefiting the most.
引用
- Saad AF, Pedroza C, Gavara R, et al. Dilapan-S vs standard methods for cervical ripening in term pregnancies: an individual patient data meta-analysis. Am J Obstet Gynecol MFM. 2024. PMID: 39674507. doi:10.1016/j.ajogmf.2024.101583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。